Sopharma AD reports sale of treasury shares worth BGN 747,218

Ognian Ivanov Donev
Ognian Ivanov Donev
0Comments

Sopharma AD has announced the sale of 303,540 treasury shares on August 25, 2025. The company reported that these shares represent 0.06% of its total share capital. The transaction was completed on the Bulgarian Stock Exchange at a total value of BGN 747,218.50, with an average price per share of BGN 2.46.

Following this sale, Sopharma AD holds a total of 20,545,342 treasury shares. This amount accounts for 3.81% of the company’s share capital.

“Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 25, 2025 the Company sold 303 540 (three hundred three thousand five hundred and forty) treasury shares representing 0.06% of the share capital of the Company, at a total value of BGN 747 218.50 on the Bulgarian Stock Exchange, the average price per share was BGN 2.46.”

The disclosure follows requirements set out by art. 17 of Regulation (EU) No 596/2014 from the European Parliament and Council.

The company remains listed on both the Bulgarian Stock Exchange and Warsaw Stock Exchange.



1 Comments
  • Sign up to get 100 USDT says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Your point of view caught my eye and was very interesting. Thanks. I have a question for you. https://www.binance.com/pt-BR/register?ref=GJY4VW8W
  • Related

    Paul Hudson Chief Executive Officer Sanofi SA

    Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

    Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

    Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

    Volvo announces updated share and vote count after series conversion

    The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

    Paul Hudson Chief Executive Officer Sanofi SA

    Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

    Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

    Trending

    The Weekly Newsletter

    Sign-up for the Weekly Newsletter from EU Business Daily.